News Merck suffers a setback in its TIGIT programme Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
News Merck’s cardiovascular pipeline delivers at ACC Data on sotatercept in PAH and oral PCSK9 MK-0616 boost Merck's hopes for the franchise.
News Merck drops last phase 3 Keytruda trial in prostate cancer KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.
News Merck will appeal EU rejection of COVID drug Lagevrio CHMP says evidence for the drug is “not adequate” to show efficacy over standard care.
News Could Daiichi Sankyo have another ADC winner in cancer? New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
